Home/Pipeline/LTCR‑H3‑3

LTCR‑H3‑3

Biomarker study for advanced primary HBV‑HCC

Phase 1Upcoming

Key Facts

Indication
Biomarker study for advanced primary HBV‑HCC
Phase
Phase 1
Status
Upcoming
Company

About Lion TCR

Pioneering mRNA‑based TCR‑T cell immunotherapy for HBV‑driven liver cancer in Asia.

View full company profile